GlassScriptPhysician profile
Janna B Davis
NPI 1689930489
$4,215.59
in general payments reported to CMS, 2019-2025
30 companies · $1,501 in 2025
The $1,501 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.73 · 2020: $59.40 · 2021: $21.35 · 2022: $381 · 2023: $736 · 2024: $1,439 · 2025: $1,501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,676.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $778.23 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $660.50 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $486.18 | 2019-2025 | |
| Exact Sciences Corporation | $240.77 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $187.51 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $187.47 | 2023-2025 | Veozah |
| Abbvie INC. | $183.90 | 2022-2025 | Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.30 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $174.79 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Corcept Therapeutics | $147.03 | 2024-2025 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $113.22 | 2022 | |
| Lundbeck LLC | $111.18 | 2024-2025 | Vyepti |
| Astrazeneca Pharmaceuticals LP | $109.29 | 2019-2024 | Airsupra, Farxiga |
| Amgen INC. | $90.47 | 2024-2025 | Evenity, Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $76.38 | 2024 | Voquezna |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $61.12 | 2025 | Gemtesa, Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $55.70 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $53.25 | 2023-2024 | Xarelto |
| Ironshore Pharmaceuticals INC. | $53.04 | 2022-2023 | Jornay Pm |
| Gilead Sciences, INC. | $42.65 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.38 | 2024-2025 | Xifaxan |
| Dexcom, INC. | $24.27 | 2025 | Dexcom G6 Transmitter |
| Neos Therapeutics, LP | $23.81 | 2023 | Adzenys Xr-Odt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.55 | 2025 | Caplyta |
| Dynavax Technologies Corporation | $23.52 | 2024 | Heplisav-B |
| Merck Sharp & Dohme LLC | $22.94 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $21.35 | 2021 | |
| Amarin Pharma, INC. | $17.89 | 2020 | |
| Nevro Corp. | $15.99 | 2024 | Senza |
| Teva Pharmaceuticals USA, INC. | $15.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janna Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.